Alimentary Pharmacology & Therapeutics

The pharmacology of the internal anal sphincter and new treatments of ano-rectal disorders
pp. 887-898(12)
Authors: Cook, T. A.; Brading, A. F.; Mortensen, N. J. McC.

Photodynamic therapy and the alimentary tract
pp. 899-915(17)
Authors: Selvasekar, C. R.; Birbeck, N.; Mcmillan, T.; Wainwright, M.; Walker, S. J.

Proton pump inhibitors versus H₂-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer
pp. 917-926(10)
Authors: Gisbert, J. P.; González, L.; Calvet, X.; Roqué, M.; Gabriel, R.; Pajares, J. M.

The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety
pp. 927-935(9)
Authors: Vakil, N. B.; Shaker, R.; Johnson, D. A.; Kovacs, T.; Baerg, R. D.; Hwang, C.; D'Amico, D.; Hamelin, B.

The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects—male and female, elderly and young
pp. 937-944(8)
Authors: Appel-Dingemanse, S.; Horowitz, A.; Campestrini, J.; Osborne, S.; Mcleod, J.

Healthcare resource utilization in the management of oesophageal adenocarcinoma
pp. 945-951(7)
Authors: Soni, A.; Sonnenberg, A.

High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C
pp. 953-958(6)
Authors: Di Marco, V.; Vaccaro, A.; Ferraro, D.; Alaimo, G.; Rodolico, V.; Parisi, P.; Peralta, S.; Di Stefano, R.; Almasio, P. L.; Craxì, A.

Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials
pp. 959-964(6)
Authors: Longstreth, G. F.; Hawkey, C. J.; Mayer, E. A.; Jones, R. H.; Naesdal, J.; Wilson, I. K.; Peacock, R. A.; Wiklund, I. K.

Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial
pp. 965-972(8)
Authors: Testoni, P. A.; Bagnolo, F.; Andriulli, A.; Bernasconi, G.; Crotta, S.; Lella, F.; Lomazzi, A.; Minoli, G.; Natale, C.; Prada, A.; Toti, G. L.; Zambelli, A.

Impaired bioavailability of vitamin A in adults and children with persistent diarrhoea in Zambia
pp. 973-979(7)
Authors: Kelly, P.; Musuku, J.; Kafwembe, E.; Libby, G.; Zulu, I.; Murphy, J.; Farthing, M. J. G.

Reliability and validity of the digestive health status instrument in samples of community, primary care, and gastroenterology patients
pp. 981-987(7)
Authors: Shaw, M. J.; Beebe, T. J.; Adlis, S. A.; Talley, N. J.

Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer
pp. 989-999(11)
Authors: Konturek, P. C.; Konturek, S. J.; Sulekova, Z.; Meixner, H.; Bielanski, W.; Starzynska, T.; Karczewska, E.; Marlicz, K.; Stachura, J.; Hahn, E. G.

The Loiano-Monghidoro population-based study of Helicobacter pylori infection: prevalence by ¹³C-urea breath test and associated factors
pp. 1001-1007(7)
Authors: Bazzoli, F.; Palli, D.; Zagari, R. M.; Festi, D.; Pozzato, P.; Nicolini, G.; Masala, G.; Fossi, S.; Ricciardiello, L.; Panuccio, D.; Roda, E.

Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong
pp. 1009-1015(7)
Authors: You, J. H. S.; Lee, K. K. C.; Ho, S. S. S.; Sung, J. J. Y.; Kung, N. N. S.; Yung, M.; Lee, C.; Yee, G. C.

Ranitidine bismuth citrate-based triple therapies after failure of the standard `Maastricht triple therapy': a promising alternative to the quadruple therapy?
pp. 1017-1022(6)
Authors: Perri, F.; Villani, M. R.; Quitadamo, M.; Annese, V.; Niro, G. A.; Andriulli, A.

Predictors of failure of Helicobacter pylori eradication with the standard `Maastricht triple therapy'
pp. 1023-1029(7)
Authors: Perri, F.; Villani, M. R.; Festa, V.; Quitadamo, M.; Andriulli, A.

Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole
pp. 1031-1036(6)
Authors: Pilotto, A.; Franceschi, M.; Leandro, G.; Bozzola, L.; Rassu, M.; Soffiati, G.; Di Mario, F.; Valerio, G.

Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer?
pp. 1037-1045(9)
Authors: Tepeš, B.; Križman, I.; Gorenšek, M.; Gubina, M.; Orel, I.

Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six-month follow-up study
pp. 1047-1054(8)
Authors: Hurenkamp, G. J. B.; Grundmeijer, H. G. L. M.; Van Der Ende, A.; Tytgat, G. N. J.; Assendelft, W. J. J.; Van Der Hulst, R. W. M.

Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease
pp. 1055-1059(5)
Authors: Laheij, R. J. F.; Jansen, J. B. M. J.; Verbeek, A. L. M.; Verheugt, F. W. A.

Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment
pp. 1061-1065(5)
Authors: Calvet, X.; Garcia, N.; Gené, E.; Campo, R.; Brullet, E.; Sanfeliu, I.

What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis
pp. 1067-1076(10)
Authors: Calvet, X.; Gené, E.; LÓpez, T.; Gisbert, J. P.

Comparison of the effects of concanavalin-A and epidermal growth factor on epithelial cell proliferation in the rat intestine
pp. 1077-1084(8)
Authors: Fitzgerald, A. J.; Jordinson, M.; Rhodes, J. M.; Singh, R.; Calam, J.; Goodlad, R. A.

Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors
pp. 1085-1085(1)
Authors: Neal, Keith; Logan, Richard

Reply-potential gastrointestinal effects of longterm acid suppression with proton pump inhibitors
pp. 1085-1086(2)
Author: Laine, Loren